- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03897205
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Antibodies to human leukocyte antigens (HLAs) have a strong correlation with allograft injury and loss. Treatment with imlifidase, PE and immunoabsorption (IA) all aim to reduce antibody levels.
This study compared the reduction in DSA levels after treatment with imlifidase and PE in patients diagnosed with active or chronic active AMR (according to Banff 2017 or Banff 2019 criteria) having at least a 25% rise in serum creatinine compared with last measurement prior to the AMR. (Patients with delayed graft function and AMR within 10 days after kidney transplantation could be included regardless of serum creatinine level.) Eligible patients were randomized to either 1 dose of imlifidase (0.25 mg/kg) or 5-10 sessions of PEs (IA could replace PE at the discretion of the investigator).
All patients received pulse methylprednisolone Day 1 to Day 3, followed by a tapering schedule with prednisolone/prednisone. Patients randomised to imlifidase received their first dose of methylprednisolone before imlifidase was administered. The patients did also receive high dose intravenous immunoglobulin (IVIg) 3 days after imlifidase treatment or directly after the last PE. In addition a single dose of rituximab was given 5 days after completed IVIg infusion.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia, 5000
- Royal Adelaide Hospital
-
Sydney, Australia
- Royal Prince Alfred Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
-
-
-
-
Vienna, Austria, 1090
- Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW
-
-
-
-
-
Bordeaux, France, 33076
- Hopital Pellegrin
-
Grenoble, France, 38043
- CHU Grenoble Alpes - Néphrologie, dialyse et transplantation
-
Paris, France, 75475
- Hôpital Saint-Louis. Service de Néphrologie et Transplantation
-
Paris, France, 75743
- Hôpital Necker - Service de Néphrologie - Transplantation
-
-
-
-
-
Berlin, Germany, 13353
- Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover
-
-
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10016
- New York University Grossman School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed Informed Consent obtained before any study-related procedures
- Willingness and ability to comply with the protocol
- Male and/or female donor kidney recipients age ≥18 years at the time of screening
- Presence of DSA(s)
- Meet the Banff 2017 criteria for active or chronic active AMR
- At least 25% rise in serum creatinine compared to last individual value taken prior to the AMR. Patients with delayed graft function and AMR within 10 days after transplant (confirmed by kidney biopsy) can be included regardless of serum creatinine level
- Women of child-bearing potential willing or able to use at least one highly effective contraceptive method throughout the study. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly
- Men willing to use double-barrier contraception from the first day of treatment until at least 2 months after the dose of imlifidase, if not abstinent
Exclusion Criteria:
- Previous treatment with imlifidase
- Previous high dose IVIg treatment (2 g/kg) within 28 days prior to inclusion
- Lactating or pregnant females
- Significantly abnormal general serum screening lab results judged inappropriate for inclusion in the study by the investigator
- Intake of other investigational drugs within 5 half-lives (or similar) of the product prior to inclusion
- Clinically relevant active infection(s) as judged by the investigator
- Any condition that in the opinion of the investigator could increase the subject's risk by participating in the study such as severe immune deficiency and severe cardiac insufficiency [New York Heart Association (NYHA) Class IV] or severe uncontrolled heart disease
- Known allergy/sensitivity to imlifidase, IVIg and/or rituximab and the respective excipients
- Patient unable to tolerate treatment with plasmapheresis or immunoadsorption, as judged by the investigator
- Unsuitable to participate in the study for any other reason as judged by the investigator
- Positive polymerase chain reaction (PCR) test for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection
- Current diagnosis or history of thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imlifidase
Subjects randomized to imlifidase treatment received one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
|
Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
Other Names:
|
Active Comparator: Plasma Exchange
Subjects randomized to plasma exchange (PE) treatment received 5-10 sessions of PE, as judged by the investigator.
Immunoadsorption (IA) could replace PE, at the discretion of the investigator.
|
The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline.
IA may be used instead of PE to the discretion of the investigator.
IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of Treatment
Time Frame: Start of treatment until 5 days following start of treatment
|
Maximum reduction (%) in the sum of DSA at any time point during the 5 days following the start of treatment. Only DSA with ≥1000 mean fluorescence intensity (MFI) at pre-treatment were included in the calculations. Clarification: The higher the maximum reduction percentage the lower the remaining DSA level. |
Start of treatment until 5 days following start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in DSA Levels After Treatment
Time Frame: Screening until Day 180
|
DSA levels were assessed at all visits throughout the study.
The results are presented as reduction (%) from baseline.
Clarification: The higher the reduction percentage the lower the remaining DSA level.
Please observe that a negative reduction value represents an increase in DSA level from baseline.
|
Screening until Day 180
|
Estimated Glomerular Filtration Rate (eGFR) Levels
Time Frame: Screening until Day 180
|
eGFR as calculated from p-creatinine is a measure of kidney function.
eGFR was assessed at all visits throughout the study.
|
Screening until Day 180
|
Urine Albumine/Creatinine Ratio
Time Frame: Pre-dose until Day 180
|
The albumine/creatinine ratio in urine is a measure of kidney function.
|
Pre-dose until Day 180
|
Number of Patients With Graft Loss Within 180 Days of Treatment
Time Frame: Screening until Day 180
|
Information on patients who experienced graft loss was collected throughout the study.
|
Screening until Day 180
|
Number of Patients With Signs or no Signs of Transplant Glomerulopathy at Day 180
Time Frame: Day 180
|
Biopsies collected 180 days after treatment were analysed for signs of glomerulopathy.
|
Day 180
|
Number of Patients With Different Types of Kidney Histopathology Throughout the Trial
Time Frame: Screening, Day 29 and Day 180
|
Kidney biopsies were assessed according to the Banff (2017) criteria at screening (baseline), Day 29, and Day 180. Abbreviations: AMR=Antibody mediated rejection, CMR=cell-mediated rejection |
Screening, Day 29 and Day 180
|
Number of Patients With Resolved AMR as Assessed by Messenger Ribonucleic Acid (mRNA) Levels
Time Frame: Screening, Day 29, and Day 180
|
Kidney biopsies were taken at screening, Day 29, and Day 180.
Changes from baseline in mRNA levels were assessed as evidence of resolved AMR.
|
Screening, Day 29, and Day 180
|
Number of Administered Plasma Exchange (PE) and Immunoadsorption (IA) Sessions
Time Frame: Day 1 to Day 180
|
Total number of administered PE and IA sessions to each treatment group are presented during the complete trial (Day 1 to Day 180) and for the time period: start of IVIg administration to Day 180.
|
Day 1 to Day 180
|
Total Serum Immunoglobulin G (IgG) Levels Until Administration of Intravenous Immunoglobulin (IVIg)
Time Frame: Pre-dose until Day 6
|
Total serum IgG levels over time following treatment until administration of IVIg. Please observe, IVIg was initiated on Day 4 (before 96 h measurement) for the imlifidase group. |
Pre-dose until Day 6
|
Number of Patients With Intact IgG, Single-cleaved IgG (scIgG), F(ab')2 Fragments Following Treatment Until Administration of IVIg
Time Frame: Start of treatment (Day 1) up to administration of IVIg on Day 4 (imlifidase group) and until administration of IVIg within Day 15 (PE group)
|
Presence of IgG, scIgG, and F(ab')2 was analysed using sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE)/western blot. Of note, IVIg was administered on Day 4 (before 96 h measurement) to patients treated with imlifidase. Hence no analyses beyond this timepoint were performed for this group. |
Start of treatment (Day 1) up to administration of IVIg on Day 4 (imlifidase group) and until administration of IVIg within Day 15 (PE group)
|
DSA Functionality Determined by C1q Analysis Pre- and Post-treatment
Time Frame: Screening until Day 6
|
An MFI value above 6000 is indicative of complement fixation.
Analysis of DSA functionality assessed as mean MFI levels was done before and after treatment.
|
Screening until Day 6
|
Pharmacokinetic (PK) Profile of Imlifidase: Cmax
Time Frame: Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
Cmax = Maximum observed plasma concentration of imlifidase following dosing
|
Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
PK Profile of Imlifidase: Tmax
Time Frame: Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
Tmax = Time point for maximum observed plasma concentration of imlifidase following dosing
|
Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
PK Profile of Imlifidase: t1/2
Time Frame: Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
t1/2 = terminal half-life of imlifidase (refers to the time required for plasma concentration of a drug to decrease by 50%) Different mathematical models are available to describe how drugs are adsorbed, distributed, metabolised, and eliminated from the body.
The time-concentration curve of imlifidase could be fitted to the so called 2-compartment model.
This model divide the body into a central and an peripheral compartment.
The central compartment consist of the plasma and tissues where the distribution is fast and the peripheral consists of tissues where the distribution of the drug is slower.
As a result the elimination of imlifidase consists of an initial phase with a short half life (alpha-t1/2) and an elimination phase with a longer half-life (beta-t1/2).
|
Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
PK Profile of Imlifidase: AUC
Time Frame: Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
Area under the imlifidase plasma concentration vs time curve (AUC)
|
Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
PK Profile of Imlifidase: CL
Time Frame: Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
Clearance (CL) of imlifidase means the volume of blood cleared of imlifidase per unit of time.
|
Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
PK Profile of Imlifidase: Volume of Distribution (V)
Time Frame: Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
Vss = volume of distribution associated with steady state VZ = volume of distribution associated with the elimination phase
|
Pre-dose, 30 min, 1 h, 2 h, 6 h, 24 h, 48 h, 72 h, 96 h, Day 6, Day 8, Day 1, and Day 15
|
Concentration of Anti-drug Antibodies (ADAs)
Time Frame: Screening until Day 180
|
Samples were collected and analysed for presence of anti-imlifidase IgG throughout the study. Imlifidase is an IgG-degrading enzyme of Streptococcus pyogenes. Patients who have been exposed to Streptococcus prior to participating in this trial tested positive for ADA also before exposure to imlifidase. |
Screening until Day 180
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Operations, Hansa Biopharma AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 16-HMedIdeS-12
- 2018-000022-66 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant Rejection
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
Rush University Medical CenterCareDxCompletedKidney Transplant Rejection | Pancreas Transplant RejectionUnited States
-
Charite University, Berlin, GermanyActive, not recruitingKidney Transplant Rejection | Antibody-mediated Rejection | Kidney Transplant FailureGermany
-
Ajay IsraniNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingKidney Transplant Rejection | Kidney TransplantUnited States
-
Hospital de Clinicas de Porto AlegreActive, not recruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant Failure | Kidney Transplant Failure and RejectionBrazil
-
University of MinnesotaWithdrawnKidney Transplant Rejection | Kidney Transplant; Complications | Kidney Transplant FailureUnited States
-
Viela Bio (acquired by Horizon Therapeutics)CompletedKidney Transplantation | Transplant Rejection | Allografts | Rejection; Transplant, KidneyUnited States
-
Columbia UniversityVeloxis PharmaceuticalsActive, not recruitingRenal Transplant Rejection | Kidney Transplant Failure and RejectionUnited States
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
-
Western Sydney Local Health DistrictNot yet recruitingKidney Transplant Rejection | Transplant Complication
Clinical Trials on Imlifidase
-
Hansa Biopharma ABCompletedKidney Transplant Failure and RejectionUnited States, Sweden, France
-
Hansa Biopharma ABActive, not recruitingKidney Transplantation in Highly Sensitized PatientsUnited States
-
Hansa Biopharma ABTerminatedKidney Transplant RejectionGermany, France, Austria
-
Cedars-Sinai Medical CenterHansa Biopharma ABCompleted
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsSpain, Finland, Sweden
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsSpain, Italy, France, Netherlands, Belgium, Austria, Czechia, Sweden, United Kingdom, Slovenia
-
Sarepta Therapeutics, Inc.Hansa Biopharma ABActive, not recruitingDuchenne Muscular DystrophySpain
-
Hansa Biopharma ABRecruitingKidney Transplantation in Highly Sensitized PatientsUnited States
-
Mårten SegelmarkHansa Biopharma ABCompletedAnti-Glomerular Basement Membrane Antibody DiseaseAustria, Czechia, Denmark, France, Sweden
-
Hansa Biopharma ABRecruitingLong Term Efficacy and SafetySpain, Czechia